Human Polyclonal Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal Zaire Ebolavirus Challenge in Rhesus Macaques. (25th July 2018)

• Record Type: Journal Article
• Authors: Rosenke, Kyle; Bounds, Callie E; Hanley, Patrick W; Saturday, Greg; Sullivan, Eddie; Wu, Hua; Jiao, Jin-an; Feldmann, Heinz; Schmaljohn, Connie; Safronetz, David
• Is Part Of: Journal of infectious diseases. Volume 218(2018)Supplement 5
• Page Start: S658
• Page End: S661
• Publication Date: 2018-07-25
• Subjects: Ebola virus -- transchromosomal bovines (TcB) -- polyclonal antibodies -- protection; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiy430
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Antibody therapy has been used to treat a variety of diseases and the success of ZMapp and other monoclonal antibody-based therapies during the 2014–2016 West African Ebola outbreak has shown this countermeasure can be a successful therapy for Ebola hemorrhagic fever. This study utilized transchromosomal bovines (TcB) vaccinated with a DNA plasmid encoding Ebola virus glycoprotein sequence to produce human polyclonal antibodies directed against Ebola virus glycoprotein. When administered 1 day postinfection, these TcB polyclonal antibodies provided partial protection and resulted in a 50% survival rate following a lethal challenge of Ebola virus Makona in rhesus macaques.